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There are numerous health-related quality of life (HRQol) measurements used in coronary
heart disease (CHD) in the literature. However, only values assessed with preference-
based instruments can be directly applied in a cost-utility analysis (CUA).
Objective
To summarize and synthesize instrument-specific preference-based values in CHD and the
underlying disease-subgroups, stable angina and post-acute coronary syndrome (post-
ACS), for developed countries, while accounting for study-level characteristics, and within-
and between-study correlation.
Methods
A systematic review was conducted to identify studies reporting preference-based values in
CHD. A multivariate meta-analysis was applied to synthesize the HRQoL values. Meta-
regression analyses examined the effect of study level covariates age, publication year,
prevalence of diabetes and gender.
Results
A total of 40 studies providing preference-based values were detected. Synthesized esti-
mates of HRQoL in post-ACS ranged from 0.64 (Quality of Well-Being) to 0.92 (EuroQol
European”tariff”), while in stable angina they ranged from 0.64 (Short form 6D) to 0.89
(Standard Gamble). Similar findings were observed in estimates applying to general CHD.
No significant improvement in model fit was found after adjusting for study-level covariates.
Large between-study heterogeneity was observed in all the models investigated.
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Conclusions
The main finding of our study is the presence of large heterogeneity both within and
between instrument-specific HRQoL values. Current economic models in CHD ignore this
between-study heterogeneity. Multivariate meta-analysis can quantify this heterogeneity
and offers the means for uncertainty around HRQoL values to be translated to uncertainty
in CUAs.
Introduction
A large number of health-related quality of life (HRQoL) measures for patients with coronary
heart disease (CHD) is available in the literature[1–4]. Those measures either describe the
HRQoL of patients suffering from CHD overall or distinguish across patients suffering from
one of the underlying forms of CHD, specifically stable angina or post-acute coronary syn-
drome (post-ACS). This interest in estimating the level of HRQoL in CHD is mainly due to its
increasing economic and clinical burden [5], the number of CHD prevention and treatment
strategies available, and the necessity to assess the impact of a treatment on HRQoL for use as
input parameter in cost-utility analyses (CUAs) [6,7].
From the abundance of HRQoL measurements in CHD, only the preference-based HRQoL
values can be directly applied in CUA [6,8]. These values express the individual’s preference
for living with CHD compared to other health states on an interval scale where the value of
zero is assigned to death, and the value of one to full health [7]. Preference-based values can be
generated with direct elicitation techniques, such as the time trade-off (TTO), the standard
gamble (SG) and the rating scale (RS). Another approach is based on multi-attribute question-
naires, such as the EuroQol 5D (EQ-5D), Short form 6D (SF-6D), health utility index (HUI)
and the quality of well-being (QWB) scale [7].
There is significant variation in the published literature with respect to the preference-based
HRQoL value of patients with CHD [1,9–11]. Methodological differences between direct pref-
erence-based techniques such as the exact specifications of the questions on individuals’ prefer-
ences, have been shown to have considerable impact on HRQoL values [7]. Some of the
differences in HRQoL values measured with preference-based multi-attribute instruments
reflect the variation across instruments on the sensitivity of different health attributes across
different severity levels as well as the use of different direct valuation techniques [7]. Finally,
HRQoL values can largely vary due to differences in study-level covariates such as patients’
characteristics (e.g. underlying CHD forms, age, and comorbidities), types of treatment applied
or time points of measuring HRQoL relative to the disease onset or treatment initiation.
All the aforementioned differences in the underlying methodology indicate that the choice
of the HRQoL value to be applied in CUA needs to consider the impact of both instrument-
specific properties and study-level covariates. Notably, when selecting a HRQoL value from the
published literature, an evidence synthesis can provide better estimates around the mean and
variance of HRQoL to inform CUA than a single study value. The application of meta-analysis
on HRQoL values is straightforward when all values are measured with the same instrument.
However, a number of studies provide multiple and correlated HRQoL values measured in the
same population but using different instruments. Conducting separate univariate meta-analy-
ses for each HRQoL is inappropriate as ignoring the within-study correlation might lead to
biased mean and standard error (SE) estimates [12,13]. Instead, multivariate meta-regression
analysis is recommended [12,13]. Therefore, in this study we aim to systematically summarize
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and synthesize the published preference-based HRQoL values in CHD and its underlying dis-
ease-subgroups (i.e. stable angina and post-ACS) for developed countries. To account for the
underlying differences in the instruments used to measure the HRQoL, and the correlation
between instrument-specific values both within and between studies, the synthesis of values is
conducted on an instrument-specific level. Additionally, the impact of study-level covariates
on HRQoL is explored in regression analysis.
Methods
Data collection
This study was conducted following the PRISMA guidelines and a checklist for their applica-
tion in provided in S1 Appendix. Relevant studies reporting HRQoL in CHD were indepen-
dently screened and systematically reviewed by two team members [JS and PP]. Studies were
searched using MEDLINE and EMBASE. The search terms used were: (“coronary disease” or
“coronary heart disease” or “myocardial infarction” or “angina” or “acute coronary syndrome”)
and (“utility” or “quality of life” or “outcome assessment”) and ("Health Utilities Index" or
"quality of well-being" or "rating scale" or "standard gamble" or "time trade-off" or "15D" or
"SF-6D" or "EQ-5D" or "HALex"). See S2 Appendix for details of search strategy for MEDLINE
and EMBASE. The search was limited to studies applying to developed countries published
between 1990 and November 2014. The last search was conducted on the 15th of December
2014. By including only studies from developed countries, we aimed to limit the variation on
HRQoL associated with the relation between socio-economic status and HRQoL [14]. Addi-
tionally, the references of the identified articles and other systematic reviews were searched for
relevant studies not included in the above-mentioned databases (snowballing). Studies were
considered eligible for this analysis if they: 1) applied a preference-based instrument of measur-
ing HRQoL (TTO, SG, RS, EQ-5D, SF-6D, SF-15D, HUI, QWB and HALex) 2) reported mean
preference-based HRQoL values measured three months or more after the initiation of CHD-
treatment or after the onset of CHD, 3) reported standard deviations (SDs) and sample sizes or
confidence intervals (CIs)/SEs of those measurements. Duplicate studies were excluded as well
as editorials, letters, clinical conference abstracts, reviews and studies that reported median but
not mean HRQoL values. Disagreements were resolved through discussion.
Data from the eligible studies were extracted in duplicate by two team members [JS and
PP]. Any uncertainties were resolved by discussion. Data were extracted regarding study origin
(authors, publication year, country), study design, participants (age, study sample, percentage
of men, percentage of diabetics, underlying form of CHD) as well as the HRQoL (mean value,
SD or CI/SE of the mean), type of instrument for measuring HRQoL and correlation coeffi-
cients between instrument-specific values. Moreover, for the HRQoL measured with the EQ-
5D, we recorded a ‘tariff’ applied to the EQ-5D questionnaire data to generate preferences. Tar-
iffs present valuation sets for EQ-5D health states derived using the TTO technique in nation-
ality-specific population samples [7].
Assumptions and data adjustments
We distinguished between two underlying CHD subgroups: stable angina and post-ACS. The
stable angina and the post-ACS groups comprised of stable angina patients and patients with
unstable angina or myocardial infarction, respectively, in whom HRQoL was measured at least
three months after diagnosis or treatment initiation. Our analysis was limited to HRQoL values
measured three months after onset of CHD or treatment initiation hypothesizing that the
impact of the acute disease onset or a treatment effect on HRQoL will be stabilized by then.
Additionally, all the values identified, including the ones subgrouped to stable angina, post-
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ACS and the ones for which information on patients’ characteristics were insufficient to pro-
vide their allocation to either of the two underlying CHD subgroups, were analysed together as
a general CHD group.
Furthermore, no distinction was made between the HRQoL values measured in patient sub-
groups other than the ones reflecting underlying CHD subgroups (e.g. different treatment or
socio-economic subgroups). In cases where studies provided HRQoL values in a subgroup clas-
sification that was not of interest, the HRQoL values across subgroups were synthesized to pro-
vide a weighted mean and variance estimate for a specific CHD form per study.
Statistical model
Amultivariate meta-analysis was used to estimate synthesized, instrument-specific HRQoL
estimates in post-ACS, stable angina and general CHD [12]. This approach accounts for the
correlation (both within and between studies) between HRQoL values assessed with different
instruments and was extended to a multivariate meta-regression analysis to account for the
impact of study-level covariates where appropriate. The general structure of the model applied
is presented below in matrix form.
γ i ¼ Xiβi þ δi þ εi i ¼ 1; . . . ; n ð1Þ
Here yi stands for a vector of size p whose elements comprise the instrument-speciﬁc
HRQoL values for study i, Xi is a matrix of p instruments and k covariates, βi is the vector of
regression coefﬁcients of size k, δi is a vector of random-effects terms of size p and εi is a vector
of random sampling errors of size p. We assumed that δi~MVN(0,Δ), where
Δ ¼










Here Δ represents the between-study variance–covariance matrix and its elements are t2p,
the between-study instrument-speciﬁc variance, and ρτ(jj0), the between-study correlation coef-
ﬁcient assessed when measuring the HRQoL values with j and j0 instruments. Additionally, it
was assumed that εi~MVN(0,Si), where
Si ¼










The matrix Si is the within-study variance–covariance matrix with elements s2ip, the within-
study instrument-speciﬁc variance and ρjj0, the within-study correlation coefﬁcient.
A common problem in multivariate meta-regression is the presence of missing data for vari-
ables of interest in eligible studies. In our analysis, missing data were anticipated for some of
the yi elements and their corresponding variances, as well as for some within-study correlation
coefficients. Missing values in yi may occur when HRQoL in a particular study was not esti-
mated with all the instruments included in the meta-regression. We resolved this by setting the
missing values in yi as equal to zero and their corresponding variances equal to an arbitrary
large number (1,000) (11). In this way the contribution of these values to the summarized
HRQoL estimate was insignificant. The problem related to missing values of ρjj0 was resolved
by retrieving correlation estimates from a more general population without severe
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comorbidities. Elements of ρjj0 that still remained missing were assumed to be equal to zero
[13]. In order to observe the impact of ignoring the presence of correlation and to account for
possibly different values of correlation coefficients, we undertook a sensitivity analysis by
assuming correlation coefficients to take values of 0 and 0.5 [15].
In the regression analysis, the covariates incorporated in Xi were examined for their statisti-
cal significance and their impact on reducing some of the between-study heterogeneity on
those HRQoL values. Age, publication year, prevalence of diabetes and gender were the covari-
ates examined. Following reasons were employed when choosing covariates: age and gender
were previously shown to impact HRQoL [16]; diabetes is a commonly present comorbidity in
patients with CHD, and is indicated to be associated with a reduced level of HRQoL (Coffey
et al, 2002)[17]; publication year was explored to assess a possible improvement in HRQoL
through time. There are no guidelines to suggest the minimal number of studies per outcome
of interest (i.e. an instrument-specific HRQoL value) required for the regression analysis to be
plausible in the multivariate setting. For this reason, we adopted the guidelines for the univari-
ate setting that suggest a data set sample size of approximately 10 measurements may be suffi-
cient for conducting a regression analysis with one covariate at a time [15]. The regression
analysis was limited to those outcomes where at least 10 measurements were available.
In order to indicate the extent of heterogeneity in the true population level of HRQoL that is
unexplained by study-level covariates and random sampling error in the multivariate setting,
we calculated the I2R and I
2
H statistics, recently suggested by Jackson et al [18]. We used I
2
H to
measure the impact heterogeneity for all HRQoL estimates jointly and the I2R statistic to mea-
sure the level of heterogeneity both jointly and separately for instrument-speciﬁc HRQoL esti-
mates [18]. For the estimation of the I2R, the R
2 statistic was used as a basis. In the multivariate
setting, the R2 statistic can be interpreted as the ratio of the volumes of CIs for summarized
estimates under the random effect model and the volumes of CIs for summarized estimates
under the ﬁxed effects models [18]. Under such a notation of the R2 statistic, Jackson et al. sug-
gested that the I2R can be estimated as I
2
R ¼ R2  1ð Þ=R2 [18]. Furthermore, the I2H statistic,
was estimated as I2H ¼ H2  1ð Þ=H2, where theH2 statistic represents the ratio of a general-
ized version of Cohran’s Q statistic and its associated degrees of freedom [18].
The multivariate meta-regression analysis was performed using the package mvmeta [19] in
the statistical software R (version 2.15.3) [20].
Results
Study characteristics
The process of study selection and extraction is presented in a PRISMA flow chart (Fig 1). A
total of 40 eligible studies representing over 30,575 patients were identified after the inclusion
and exclusion criteria were applied. A list of all potentially-eligible studies with reasons for
exclusion is presented in S3 Appendix. The main characteristics of these studies are detailed in
Table 1 [1–4,9–11,16,21–52]. The studies were published between 1991 and 2014, with most of
them between 2005 and 2010. Of the 40 studies included, 10 referred to the UK, 8 to the US, 6
to the multiple country settings, 4 to Germany, 3 to Canada and Finland, 2 to Norway and Swe-
den, and 1 to each of Australia and Korea. Various study designs were implemented, ranging
from randomised clinical trial to different observational study designs. Of the HRQoL values
present in those 40 studies, 31% were observed in patients with stable angina and 29% in
patients with post-ACS. The remaining 40% of the HRQoL values were associated with patients
suffering from any form of CHD (including stable angina and post-ACS). The majority of
patients were men (71%) with an average age of 65.35 years. There was large variation in
patients’ characteristics, such as the presence and prevalence of various comorbidities (e.g.
Utilities in Coronary Heart Disease: Multivariate Meta-Analysis
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prevalence of diabetes was in range 7–38%), and treatment under evaluation (e.g. surgical pro-
cedures, pharmacological treatment or cardiovascular rehabilitation) across the studies. When
reported, the time of HRQoL assessment from disease onset or treatment initiation was
between 4 months and 10 years.
The most commonly applied instrument for measuring HRQoL values was the EQ-5D
(63.5%), while 15D, QWB, SF-6D, HUI, SG, TTO, RS and HALex were less prevalent (7.7, 7.7,
5.8, 5.8, 3.8, 1.9, 1.9 and 1.9%, respectively). The values measured with the EQ-5D instrument
varied by the TTO “tariffs” utilized (i.e. UK, US, Europe and Korea). The scoring of most of the
EQ-5D values was based on the UK “tariff” (53%) while US, European and Korean “tariff”
were less present (19, 8, 8 and 3%, respectively). Three studies provided no explicit information
on the EQ-5D scoring “tariff” used, however, in order to allow for the evidence synthesis these
values were grouped together with the UK “tariffs”. The values measured with the HUI instru-
ment were presented in the studies as both mark 2 (i.e. HUI2) and mark 3 (i.e. HUI3).
Finally, the correlation coefficients between the instrument-specific HRQoL values, neces-
sary for conducting a multivariate meta-analysis on the data set formed, were reported in only
one of the studies included in the data set [31]. Therefore, some of the correlation coefficients
were retrieved from other studies on cardiovascular patients or general populations without
severe comorbidities (S1 Table) [31,53,54–57]. Nevertheless, a great number of within the
instrument-specific correlation coefficients remained missing.
Multivariate meta-analysis estimates in post-ACS, stable angina, and
general CHD
Table 2 summarizes the instrument-specific estimates synthesized through multivariate meta-
analysis in the post-ACS, stable angina subgroups, and general CHD assessed on the full data
set. The values for estimates synthesized in post-ACS ranged from 0.64 (QWB) to 0.92 (EQ-5D
European”tariff”), while in stable angina estimates ranged from 0.64 (SF-6D) to 0.89 (SG). In
general CHD, the values ranged from 0.60 (HALex) to 0.89 (SG). Between-study SDs and vari-
ance-covariance matrices for HRQoL in the post-ACS and stable angina subgroups, and gen-
eral CHD, when these parameters could be estimated, are reported in S2–S4Tables.
In this evidence synthesis, some of the instrument-specific HRQoL values included in the
data set were present only as single inputs. Notably, the output of the multivariate meta-
Fig 1. PRISMA flow diagram summarizing the study selection process. HRQoL, health-related quality of
life; SD, standard deviation; SE, standard error; CI, confidence interval.
doi:10.1371/journal.pone.0152030.g001
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analysis in the aforementioned cases reflected the initial instrument-specific HRQoL inputs.
Because the EQ-5D UK”tariff” values were the only instrument-specific values available as
multiple inputs in both post-ACS and stable angina subgroups, a relatively fair comparison of
the level of summarized HRQoL between the two subgroups would only be possible for this
instrument-specific subgroup. This comparison indicated slightly lower estimates in post-ACS
(i.e. 0.76) than the ones in stable angina (i.e. 0.78).
Large variations are noticeable across instrument-specific estimates of HRQoL in CHD pre-
sented in Table 2. The highest level of HRQoL was observed for the SG, TTO and 15D esti-
mates, which were followed by slightly lower EQ-5D and HUI estimates, while the RS, SF-6D,
QWB and HALex were the instruments with lowest HRQoL estimates.
Interestingly, substantial unexplained between-study but within-instrument heterogeneity
was observed in all the multivariate meta-analysis models with the most excessive levels of het-
erogeneity observed in general CHD assessed on the full dataset (Table 2). There was a general
agreement between both I2H and I
2
R statistics on the level of heterogeneity.
Regression analysis
The EQ-5D UK “tariff” values were the only instrument-specific values available with more
than 10 observations per instrument used and therefore in line with our requirement for
regression analysis. This led to reducing the analysis from a multivariate to a univariate meta-
regression. Table 3 presents the EQ-5D UK “tariff” estimates synthesized through a univariate
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* The time point of measuring HRQoL relative to the disease onset or treatment application
HRQoL, quality of life; SE, standard error; ACS, acute coronary syndrome; CHD, coronary heart disease; HALex, Health and Activity Limitation Index;
HUI, health utility index; QWB, quality of well-being; RS, rating scale; SG, standard gamble; TTO, time trade-off; UK, United Kingdom; US, United States;
RCT, randomized clinical trial; NA, not available; MI, myocardial infarction; MT, medical treatment; CABG, coronary artery bypass graft; CPB,
cardiopulmonary bypass; OPCAB, off-pump coronary artery bypass; SES, socio-economic status; CAD, coronary artery disease; CML, case method
learning; CR, cardiac rehabilitation; GP, general practitioner; PCI, percutaneous coronary intervention; CCSG; Canadian Cardiovascular Society
Classiﬁcation for Angina Pectoris; LVEF; left ventricular ejection fraction
doi:10.1371/journal.pone.0152030.t001
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diabetes and of men was examined on the HRQoL. Here, increasing age was found to generally
reduce the level of HRQoL while prevalence of diabetes and higher proportion of men
increased its level. The impact of publication year was inconclusive. However, none of the
covariates examined was found to provide a significant improvement in the model fit nor did
they reduce the between-study heterogeneity (Table 3).
Sensitivity analysis on the correlation coefficients between instrument-specific values was
undertaken. The result of this sensitivity analysis was that the model was overall robust to dif-
ferent values of the correlation coefficients (S5 Table). Moreover, the SEs of instrument-specific
estimates were generally insensitive to ignoring the correlation between the instrument-specific
values or setting the values of correlation coefficients to 0.5.
Discussion
This is the first study that systematically summarized and synthesized instrument-specific pref-
erence-based HRQoL values in CHD, and its underlying disease-forms, post-ACS and stable
angina in developed countries. Pooled mean HRQoL values were estimated and a large varia-
tion was observed both within and between the instrument-specific values. This variation
could be explained by the large underlying heterogeneity in the study populations, and the
observed and unobserved variation between the HRQoL instruments. Other factors possibly
include the impact of treatment applied, initial (acute) disease severity level, national and
socio-economic characteristics, various comorbidities present or the time of assessment. More-
over, the fact that TTO “tariffs” derived in nationality-specific population samples for the pref-
erence-based scoring of the EQ-5D vary across countries [58], suggests possible larger
variations in the HRQoL values in CHD patients from various national or multinational set-
tings. Additional arguments emphasize that unobservable differences in cultural or socio-
Table 2. Post-acute coronary syndrome, stable angina, and general CHD parameter estimates for HRQoL andmultivariate heterogeneity statistics
usingmultivariate meta-analysis.
Instrument N Post-ACS subgroup I2H I
2
R
N Stable angina subgroup I2H I
2
R
N CHD (full dataset) I2H I
2
R
15D 1 0.8816 (0.0074) 1 0.8515 (0.0037) 4 0.8495 (0.0069) 99.9%
EQ-5D Europe 1 0.9170 (0.0105) 3 0.7915 (0.0625) 99.7%
EQ5D Korea 1 0.8310 (0.0090)
EQ-5D UK 8 0.7638 (0.0246) 99.3% 7 0.7792 (0.0250) 99.4% 22 0.7591 (0.0122) 99.7%
EQ-5D US 3 0.7662 (0.0308) 97.3% 1 0.6950 (0.0201) 7 0.8012 (0.0128) 98.0%
HALex 1 0.5967 (0.0075)
HUI2 1 0.7626 (0.0061)
HUI3 1 0.7350 (0.0111) 2 0.7259 (0.0118) 63.5%
QWB 1 0.6400 (0.0175) 2 0.6517 (0.0097) 97.5% 4 0.6287 (0.0189) 99.4%
RS 1 0.6900 (0.0150)
SF-6D 2 0.6413 (0.0017) 51.9% 3 0.6859 (0.0131) 99.3%
SG 2 0.8889 (0.0492) 99.9% 2 0.8889 (0.0492) 99.9%
TTO 1 0.8700 (0.0026) 1 0.8700 (0.0026)
86.8% 70.7% 68.1% 92.7% 91.2% 93.9%
N presents the number of instrument-speciﬁc HRQoL values used for estimation.
All model coefﬁcients with the level of signiﬁcance p < 0.001 are presented in bold.
Standard errors of parameter estimates are showed in parentheses.
ACS, acute coronary syndrome; CHD, coronary heart disease; HRQoL, health-related quality of life; UK, United Kingdom; US, United States; HALex,
Health and Activity Limitation Index; HUI, health utility index; QWB, quality of well-being; RS, rating scale; SG, standard gamble; TTO, time trade-off.
doi:10.1371/journal.pone.0152030.t002
Utilities in Coronary Heart Disease: Multivariate Meta-Analysis
PLOS ONE | DOI:10.1371/journal.pone.0152030 March 24, 2016 12 / 20
economic status may also be present in representatives of general population samples selected
for the assessment of tariffs [59]. The consequence of this would then be a greater underlying
variability in HRQoL values in CHD assessed with instruments utilizing those tariffs. In
essence, the aforementioned concerns may have a direct impact on the generalizability of coun-
try-specific HRQoL values to various national or multinational settings.
The regression analysis indicated no significant association between available study-level
covariates and HRQoL estimates. Caution is needed in the interpretation of those findings, espe-
cially when low power for testing the effect of study-level covariates on the pooled HRQoL esti-
mate is present—namely, only 22 EQ-5D UK “tariff” values were available for the regression-
analysis. However, the reduction and increase in HRQoL observed with advancing age and
higher proportion of men, respectively is in line with other published information [60]. Surpris-
ingly, studies with a higher proportion of patients with diabetes had a higher average HRQoL
estimate what contrasts the finding by Xie et al. [61]. This may be due to the missing informa-
tion of the prevalence of diabetes across the studies as well as an example of ecological fallacy.
The variation between the instruments in the HRQoL estimates observed in our study is in
agreement with the findings from other studies that demonstrated the differences across instru-
ment-specific HRQoL values [62–64](Fryback et al 2009)[65]. Similarly to the study by John-
son et al, we observed higher levels of HRQoL when summarizing the EQ-5D US “tariffs”
compared to the UK “tariffs”[58]. Additionally, SG values commonly exceed TTO values and
RS values, a finding that was also confirmed in our study [66,67]. Furthermore, our synthesized
HUI3 estimates in CHD were lower compared to the EQ-5D estimates, but similar to the
Table 3. Parameter estimates and heterogeneity statistics for the EQ-5D UK “tariff” estimates using univariate meta-regression.
Model number Model Post-ACS I2 Model number Angina I2 Model number General CHD I2
1 b0 0.7587 (0.0215) 99.6% 5 0.7542 (0.0178) 99.5% 9 0.7652(0.0165) 99.6%
bDisease type 0.0165 (0.0339) 0.0512 (0.0396)
bAge -0.0051 (0.0059) -0.0035 (0.0057) -0.0056 (0.0057)
2 b0 0.7588 (0.0347) 99.7% 6 0.7497 (0.0355) 99.6% 10 0.7604 (0.0326) 99.7%
bDisease type 0.0059 (0.0333) 0.0270 (0.0348)
bPublication year -0.0002 (0.0052) 0.0005 (0.0051) -0.0001 (0.0050)
3 b0 0.7275 (0.0510) 99.7% 7 0.7405 (0.0443) 99.7% 11 0.7340 (0.0426) 99.7%
bDisease type 0.0125 (0.0457) 0.0306 (0.0450)
bDiabetes 0.0029 (0.0024) 0.0017 (0.0026) 0.0027 (0.0022)
4 b0 0.5982 (0.1456) 99.7% 8 0.5572 (0.1325) 99.7% 12 0.5964 (0.1407) 99.7%
bDisease type 0.0028 (0.0325) 0.0540 (0.0331)
bMen 0.0024 (0.0020) 0.0028 (0.0018) 0.0025 (0.0019)
All model coefﬁcients with the level of signiﬁcance p < 0.001 are presented in bold.
Standard errors of parameter estimates are showed in parentheses.
For regression models 1–4, an intercept is provided assigned with b0, coefﬁcients bDisease type (referring to post-ACS) and in model 1 bAge, in model 2
bPublication year, in model 3 bDiabetes and in model 4 bMen. The number of EQ-5D values in post-ASC available for models 1–4 was 8.
For regression models 5–8, an intercept is provided assigned with b0, coefﬁcients bDisease type (referring to stable angina) and in model 5 bAge, in model 6
bPublication year, in model 7 bDiabetes and in model 8 bMen. The number of EQ-5D values in stable angina available for models 5–8 was 7.
For regression models 9–12, an intercept is provided assigned with b0, coefﬁcients in model 9 bAge, in model 10 bPublication year, in model 11 bDiabetes and in
model 12 bMen. The number of EQ-5D values in CHD in general available for models 19–12 was 22.
Example for interpretation: Model 4 –summary EQ-5D UK “tariff” estimate in men with post-ACS would be 0.6034 (i.e 0.5982+0.0028+0.0024), and 0.601
in women with similar characteristics (0.5982+0.0028).
ACS, acute coronary syndrome; CHD, coronary heart disease; UK, United Kingdom; b0, intercept.
doi:10.1371/journal.pone.0152030.t003
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findings of O’Brien et al. in patients at increased risk of sudden cardiac death and receiving
implantable defibrillator therapy[63]. In our study, both the summarized and study-level SF-
6D values were lower than EQ-5D values in CHD what contrasts the observations of Brazier
et al.[1,45]. We observed the lowest level of HRQoL in CHD for estimates measured with the
QWB and the HALex, what is in line with the patterns of values in general US population mea-
sured with six preference-based instruments by Fryback et al.[65] Differences such as the valu-
ation technique, bounds of scale and sensitivity to change after treatment are only some of
potential reasons for the variation between the instrument-specific HRQoL estimates [62–64].
For the evidence synthesis we applied multivariate meta-analysis given that when informa-
tion on various instrument-specific values is sparse, it allows for “borrowing of strength” from
the values available by accounting for the correlation between them [12,13]. Though such an
approach may provide more precise summarized estimates [12,13] than a meta-analysis where
the correlation is ignored, this did not hold in our study due to a high between-study variation.
Potentials for direct comparisons of our analysis to other synthesized HRQoL values are
limited due to the lack of studies meta-analysing preference-based values in CHD. A meta-
analysis of 84 studies identified to address HRQoL in cardiac patients by Kinney et al. may be
one potential comparator to our study [68]. Kinney et al. investigated the effect of pharmaco-
logical, surgical, nursing or other treatment on HRQoL and found a small positive effect of
treatment (i.e. standardised mean difference (d) = 0.31). Despite certain similarity in the
patient populations investigated between the two studies can be acknowledged, numerous dif-
ferences such as the study inclusion criteria (i.e. any measurement of HRQoL including the
ones of single health attributes), choice of study effect size (i.e. standardised mean difference),
the period of data collection (i.e. 1987–1991) and the methodology used for conducting meta-
analysis (i.e. fixed-effect model) hamper adequate comparisons.
Another comparator to our study may be a review by Dyer et al. on the EQ-5D values in car-
diovascular disease (CVD)[69]. Dyer et al. summarized and stratified the EQ-5D values across
different CVD subgroups (e.g. ischemic heart disease (IHD) such as angina/myocardial infarc-
tion/CHD, heart failure etc.) and, when feasible, across three severity level categories defined
by the percentage of patients in a given group in class III/IV of NYHA or CCS class[69]. Their
stratification of the EQ-5D values with IHD collected at baseline resulted in the range of values
from 0.45 for moderate/severe angina to 0.80 for mild angina. The authors did not synthesise
these values across different severity levels due to the high heterogeneity observed (i.e. I2 of 82–
96%), but suggested more rigorous study inclusion criteria and the possibility to expand their
data set with more recent publications (i.e. studies published after 2008) as a method to reduce
some of the heterogeneity observed[69]. However, the more rigorous inclusion criteria that our
study proposed such as the inclusion of only mean HRQoL values measured in patients in sta-
ble or post-acute disease state, and incorporating HRQoL values from a wider publication
range (i.e. 1990–2014) in the data set, did not reduce the high heterogeneity observed across
studies. Notably, the heterogeneity indices observed in the study by Dyer et al. and the ones
observed between the EQ-5D values in our study cannot be directly compared[69]. Differences
between the two data sets and the method for disease stratification (i.e. post-ACS and stable
angina subgroups vs. CCS class categories reported in ICH) are limiting such a comparison.
Our analysis is confronted with certain limitations. The main limitation of our study is that
we analysed study-level and not patient-level data. Analysing patient-level data might provide
significant improvements in our analysis. If detailed information on patients currently nonclas-
sified specific CHD from was available, this would allow for a more accurate disease-specific
allocation of HRQoL values. Conducting the multivariate meta-analysis on such a data set
could possibly lead to estimates with lower level of between-study heterogeneity. Another limi-
tation of our study was that we conducted the meta-regression analysis only on the subset of
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the EQ-5D UK “tariff” values due to a relatively small number of studies providing other
instrument-specific values. This regression analysis was also limited with the respect to the
variety of covariates investigated. Covariates such as patients’ socioeconomic status, presence
of comorbidities other than diabetes or the impact of treatment applied were not investigated
in the regression analysis due to their scarce information across the studies [70]. Expectedly,
this study was confronted with the missing information on within-study correlation coeffi-
cients. This was solved by retrieving the correlation coefficients reported in other studies on
cardiovascular patients or general populations. The sensitivity of the study results on the corre-
lation coefficients utilized was tested in the sensitivity analysis. Furthermore, the publication
bias was not formally assessed using a funnel plot due to the small number of instrument-spe-
cific HRQoL values included in this study as well as considerable heterogeneity. Also, publica-
tion bias is not expected in our meta-analysis given that the HRQoL values are commonly
measured as secondary study outcomes and, therefore, are not expected to impact the decision
to publish. Finally, information on HRQoL in CHDmeasured with non-preference-based and
disease-specific instruments was not included in our analysis.
Importantly, our study did not aim to investigate what the most appropriate and reliable
instrument to measure HRQoL in CHD is, but rather to summarize and synthesize all the avail-
able evidence of preference-based instrument-specific values. The decision on the most robust
instrument-specific estimate to be applied in a CUA depends not only on the appropriateness
and reliability of an instrument to measure HRQoL in CHD but also on its agreement with
instrument-specific values available for other health states modelled in the CUA. Furthermore,
some decision-makers might argue that considering the previously discussed reasons for coun-
try- and centre-specific variability in HRQoL values, one should simply choose a single coun-
try-specific and CHD-form specific HRQoL value. However, in the case where multiple
country-specific values exist or even a single such value is unavailable, the decision on the most
robust value becomes more complex and needs to rely on an evidence-synthesis exercise More-
over, although distinguishing between underlying CHD-forms seems as more clinically rele-
vant, CUAs in both primary and secondary prevention of CHD often model a general CHD
health state [71–74]. An evidence synthesis of all available HRQoL values may again be consid-
ered to select a robust HRQoL estimate in CHD. Such an estimate could then reflect more
appropriately the complex nature of CHD and its various manifestations. This motivated us to
consider an evidence-synthesis of HRQoL values in overall CHD.
Finally, characterizing the between study heterogeneity not only provides a better mean esti-
mate for HRQoL values used in CUA but it also provides a better understanding on the uncer-
tainty around the HRQoL value and how this translates into uncertainty around the CUA
outcomes. This uncertainty, as we showed in our study, is considerable and as it is mostly
found between studies, it is ignored when a single value from an individual study is selected.
Dias et al. proposed that in the presence of between-study heterogeneity, using the predictive
distribution is the appropriate way to characterize parameter uncertainty when embedding
synthesized evidence in CUA [75]. Researchers using the findings from this study for economic
evaluation purposes will therefore have to rely in generating values that incorporate both
within- and between-study standard deviation (predictive distribution) provided in the results
section of this article.
Conclusions
This study represents the first evidence synthesis of instrument-specific preference-based
HRQoL values in post-ACS, stable angina, and CHD in general. Considerable differences in
mean HRQoL estimates were observed both within and between the instruments. These
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differences characterized by large between-study heterogeneity may be explained by both the
observed and unobserved methodological differences across instruments and underlying
study-level characteristics. Current CUAs in CHD ignore this between-study study heterogene-
ity. Therefore, multivariate meta-analysis can facilitate quantifying this heterogeneity for
HRQoL estimates and offer the means for uncertainty around HRQoL values to be translated
to uncertainty in economic models.
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